BioInvent International Prepares to Unveil Promising Data at the 31st European Hematology Association Congress
In the lead‑up to the European Hematology Association (EHA) Congress in Stockholm, BioInvent International AB (STO:BINV) has announced a series of forthcoming presentations that highlight the company’s progress in antibody‑based therapies for hematologic malignancies. The company’s clinical pipeline, centered on novel immune‑modulatory antibodies, is poised to generate significant interest from both the scientific community and investors.
BI‑1206: Tackling Rituximab Resistance in Relapsed/Refractory Non‑Hodgkin Lymphoma
BioInvent will present a poster on “Targeting resistance to rituximab through Fc?RIIB (CD32B) blockade: BI‑1206 + rituximab + acalabrutinib shows powerful activity in R/R NHL.” The poster, scheduled for Friday, 12 June 2026, will summarize early efficacy and safety data from the Phase 1/2 trial (NCT03571568). The study investigates the triplet combination of BI‑1206, a human antibody that blocks the Fc?RIIB‑mediated internalization of rituximab, rituximab itself, and Calquence (acalabrutinib), a Bruton tyrosine kinase (BTK) inhibitor.
Pre‑publication data from the same trial have shown an objective response rate (ORR) of 80 % and 100 % disease control among assessed patients. The combination has been reported to have a favorable tolerability profile, with most adverse events classified as mild or moderate. The forthcoming poster will provide deeper mechanistic insights, safety updates, and a discussion of the clinical implications of this approach to overcoming rituximab resistance.
BI‑1808: Advancing TNFR2‑Targeted Therapy in Cutaneous T‑Cell Lymphoma
Another highlight of BioInvent’s agenda is the presentation of Phase 2a data for BI‑1808, a TNFR2‑specific antibody targeting advanced cutaneous T‑cell lymphoma (CTCL). The company will showcase the antibody’s activity both as a monotherapy and in combination with KEYTRUDA® (pembrolizumab). Key points from the preliminary data include:
| Parameter | Monotherapy | Combination with KEYTRUDA |
|---|---|---|
| Objective response rate (ORR) | 40 % | 50 % |
| Complete response in Sézary syndrome | 1 patient (ongoing > 2 years) | — |
| Immune activation | Evident | Enhanced |
| Safety | Mild–moderate adverse events | Mild–moderate adverse events |
BI‑1808’s development is supported by Fast Track and Orphan Drug Designations from the U.S. Food and Drug Administration for T‑cell lymphoma and from the European Medicines Agency for CTCL, positioning the antibody for a potentially expedited approval pathway.
Strategic Implications for BioInvent
BioInvent’s focus on antibody libraries and protein‑based drug development has positioned it as a key partner for larger biopharmaceutical firms. The forthcoming EHA presentations underline the company’s ability to translate its platform into clinically meaningful therapies. For investors, BioInvent’s current market cap of approximately 1.57 billion SEK and a recent trading price of 23.9 SEK (as of 10 May 2026) reflect a company that remains in the early‑growth stage, with a negative price‑earnings ratio indicating the need for continued investment in research and development.
The upcoming data releases may influence the company’s valuation and provide a clearer trajectory for the potential commercialization of BI‑1206 and BI‑1808. As the broader biotechnology landscape increasingly values novel immuno‑oncology approaches, BioInvent’s advances in Fc?RIIB blockade and TNFR2 targeting could serve as pivotal milestones in the fight against refractory lymphomas.
